Assessment of Burden of Disease in Terms of Health Related Quality of Life in Patients With Multiple Myeloma for Autologous Stem Cell Transplantation

Olga Delgado Sanchez, Abel Domingo, Javier de la Rubia, Antonio Garcia, Aurora Lopez, Carlos Segui, Laura Rumi, Amado Mengual, Giselle Lestanoua, Maria Victoria Matena

1. The majority of patients with NDMM are > 65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

2. QoL has become a relevant key performance indicator and a critical component of comprehensive patient care. Here, we present data on the impact of Tx on MM burden in terms of QoL.

3. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

4. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

5. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

6. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

7. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

8. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

9. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

10. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

11. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

12. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

13. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

14. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

15. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

16. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

17. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

18. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

19. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

20. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

21. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

22. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

23. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

24. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

25. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

26. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

27. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

28. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

29. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

30. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

31. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

32. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

33. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

34. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.

35. The majority of patients with NDMM are >65 years old and/or have poor physical function or multiple comorbidities. As a consequence, many are ineligible for standard Tx with high-dose chemotherapy and ASCT.